This advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. The advisory focuses on the risks and harms of CBD, especially those sold over the counter. This advisory also clarifies common misconceptions about CBD, given its broad availability and marketing for several medical conditions despite limited evidence of efficacy.

This fact sheet developed by CDC’s National Institute for Occupational Safety and Health (NIOSH) helps employers understand the risk of opioid overdose and allows them to decide if they should establish a workplace naloxone availability and use program.